This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. MOR, GMTX, CALT, ZYME, MENS, SBTX, MBX, AVTE, NLTX, and CYBNShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Travere Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Jyong Biotech Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics Cybin MorphoSys (NASDAQ:MOR) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Do institutionals & insiders believe in MOR or RTRX? 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor MOR or RTRX? In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Travere Therapeutics'average media sentiment score. Company Overall Sentiment MorphoSys Neutral Travere Therapeutics Neutral Which has more risk & volatility, MOR or RTRX? MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Which has stronger valuation & earnings, MOR or RTRX? Travere Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Travere Therapeutics$175.34M4.46-$146.43M-$3.46-4.43 Is MOR or RTRX more profitable? Travere Therapeutics has a net margin of -49.13% compared to MorphoSys' net margin of -226.79%. Travere Therapeutics' return on equity of -36.38% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Travere Therapeutics -49.13%-36.38%-14.90% SummaryTravere Therapeutics beats MorphoSys on 6 of the 11 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$782.12M$780.85M$5.72B$9.53BDividend YieldN/A4.84%4.70%4.06%P/E Ratio-7.261.4128.3420.08Price / Sales4.4626.50466.11102.40Price / CashN/A19.5625.1828.38Price / Book2.976.838.545.84Net Income-$146.43M-$4.22M$3.25B$259.02M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$15.32-3.9%N/A+54.9%$782.12M$175.34M-7.26221High Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.38+2.8%N/A+32.7%$2.57BN/A-59.3830High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4848 of 5 stars$14.32flat$21.00+46.6%+24.0%$997.86M$93.38M-9.55460Upcoming EarningsMENSJyong BiotechN/A$10.06-8.5%N/AN/A$836.30MN/A0.0031Quiet Period ExpirationSBTXSilverback TherapeuticsN/A$17.85-0.4%N/A+62.8%$643.64MN/A-7.3883High Trading VolumeMBXMBX Biosciences2.2521 of 5 stars$11.70-4.0%$37.57+221.1%N/A$391.06MN/A0.0036AVTEAerovate TherapeuticsN/A$8.69-8.2%N/A-88.2%$251.88MN/A-2.9120High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-49.3%$209.95MN/A-7.1890High Trading VolumeCYBNCybin2.6287 of 5 stars$7.73-3.7%$85.00+999.6%N/A$177.98MN/A-1.7650 Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Jyong Biotech Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTRX Stock Alerts